Meningiomas are the second most common primary brain tumor, arising from arachnoid cap cells within the meninges.
While most meningiomas are benign, there remains a subset of these tumors which are:
Higher grade and recurrent meningiomas are expected to express a unique set of surface markers when compared with benign lesions.
Identification of these antigens through the utilization of antibody staining may be important in predicting a more reliable prognosis and characterizing optimal adjuvant treatment for an individualized therapeutic strategy.
Our lab is also conducting similar research for other benign skull base tumors such as:
Lecture 31: Intracranial Meningioma from UCLA Health System on Vimeo.
The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments View Meningioma Article (PDF) »